News | February 10, 2026
GSK India crosses Rs. 1,000 crore mark, key portfolios drive 8.1% topline growth
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
Patients with BRCA mutations often face aggressive disease and poor prognosis
The company is bringing precision therapies for gynaecological cancers
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
